Calidi Biotherapeutics Unveils Promising Data on CLD-401 at ASCO 2025

Calidi Biotherapeutics Inc. (NYSE American: CLDI) has taken a significant step forward in the fight against cancer with the unveiling of promising new data on its lead RedTail platform candidate, CLD-401, at the American Society of Clinical Oncology (ASCO) Annual Meeting. This development marks a pivotal moment in the company's mission to revolutionize cancer treatment through systemic oncolytic targeted immunotherapies.

The data presented highlights a novel genetic modification involving a chimeric CD55 receptor incorporated into the virus's envelope. This innovation significantly enhances the virus's resistance to rapid clearance by the humoral immune system following intravenous administration. Such advancements in immunotherapy are crucial for improving the efficacy of treatments targeting metastatic cancers, offering hope for patients with high unmet medical needs.

Calidi Biotherapeutics' approach with the RedTail platform, featuring an engineered enveloped oncolytic virus designed for systemic delivery, represents a new frontier in cancer treatment. The ability to shield the virus from immune clearance allows for more effective targeting of metastatic sites, potentially transforming the landscape of oncology therapeutics. The implications of this research extend beyond the laboratory, promising to impact the lives of patients worldwide by providing more effective treatment options for challenging cancers.